Post-transplantation lymphoproliferative disorder and OKT3

Robert W. Emery, Kathleen D. Lake, René M.l. Brouwer, Aggie H.m.m. Balk, Willem Weimar, Jeffrey I. Cohen, A. Benedict Cosimi, Robert H. Rubin, Daniel Abramowicz, Michel Goldman, Luc de Pauw, Jean Marc Doutrelepont, Paul Kinnaert, Jean Louis Vanherweghem, Pierre Vereerstraeten, Lode J. Swinnen, Susan G. Fisher, Maria R. Costanzo-Nordin, Richard I. Fisher

Research output: Contribution to journalLetterpeer-review


To the Editor: Swinnen et al. (Dec. 20 issue) reported an 11.4 percent incidence of post-transplantation lymphoproliferative disorder associated with the administration of OKT3 in heart-transplant recipients.1 This experience is not consistent with that at the Minneapolis Heart Institute, where a prophylactic OKT3 regimen has been used in high-risk heart-transplant recipients for 45 months.2 Since May 3, 1987, 39 recipients of heart transplants have received OKT3; 31 were weaned from steroids three to six months after transplantation and have been maintained on a steroid-free regimen of cyclosporine and azathioprine. One- and three-year survival rates were 93 percent and 91 percent,. . .

Original languageEnglish (US)
Pages (from-to)1437-1439
Number of pages3
JournalNew England Journal of Medicine
Issue number20
StatePublished - May 16 1991
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Post-transplantation lymphoproliferative disorder and OKT3'. Together they form a unique fingerprint.

Cite this